Clinical Q&A

Barbara Holmes Gobel

CJON 2003, 7(1), 104-108. DOI: 10.1188/03.CJON.104-108

Question: What is the appropriate way to dose carboplatin (Paraplatin ®, Bristol-Myers Squibb, Princeton, NJ) when patients’ creatinine clearance (CrCl) are decreased or a concern exists about patients’ hematologic status (e.g., decreasing the dose after using a standard area under the curve [AUC] dosing or by choosing a lower AUC)?

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.